Figures & data
Figure 1. (a) Detailed experimental design. Physiological assays of rats with DEN/PB-induced HCC that were treated with Mulberry fruit polysaccharides (MFP). (b) The chromatograms of MFP. (c) Final body weight of rats with DEN/PB-induced HCC that was treated with MFP. (d) Liver weight of rats with DEN/PB-induced HCC that was treated with MFP. (e) Relative liver weight of rats. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. & Significant against DEN/PB+HMFP group at P < 0.05
![Figure 1. (a) Detailed experimental design. Physiological assays of rats with DEN/PB-induced HCC that were treated with Mulberry fruit polysaccharides (MFP). (b) The chromatograms of MFP. (c) Final body weight of rats with DEN/PB-induced HCC that was treated with MFP. (d) Liver weight of rats with DEN/PB-induced HCC that was treated with MFP. (e) Relative liver weight of rats. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. & Significant against DEN/PB+HMFP group at P < 0.05](/cms/asset/3524d6c4-c587-43bf-b53f-7d160096276d/kbie_a_1993716_f0001_oc.jpg)
Table 1. Sequences of primers used quantitative real-time PCR
Table 2. The chemical analysis of polysaccharides from mulberry fruit
Table 3. Effect of MFP on mortality in DEN/PB-induced hepatocellular carcinoma
Figure 2. Effect of MFP on hepatic function biomarkers in DEN/PB-induced HCC. (a) The levels of serum aspartate aminotransferase (AST), (b) alanine aminotransferase (ALT), (c) alkaline phosphatase (ALP), (d) glutamyl transpeptidase (GGT), (e) total bilirubin, and (f) albumin in different treatment groups were measured. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01
![Figure 2. Effect of MFP on hepatic function biomarkers in DEN/PB-induced HCC. (a) The levels of serum aspartate aminotransferase (AST), (b) alanine aminotransferase (ALT), (c) alkaline phosphatase (ALP), (d) glutamyl transpeptidase (GGT), (e) total bilirubin, and (f) albumin in different treatment groups were measured. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01](/cms/asset/9f95e2d0-eeb6-4404-88ef-07bd999dc8a3/kbie_a_1993716_f0002_b.gif)
Figure 3. Effect of MFP on hepatic tumor markers in DEN/PB-induced HCC. (a) The levels of serum alpha-fetoprotein (AFP), (b) carcinoembryonic antigen (CEA), and (c) carbohydrate antigen 19.9 (CA19.9) in different treatment groups were measured. (d) Representative images of immunohistochemical staining with GST-p in different groups (scale bar = 100 μm). (e) The percentage of GST-p positive cells in different groups. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01
![Figure 3. Effect of MFP on hepatic tumor markers in DEN/PB-induced HCC. (a) The levels of serum alpha-fetoprotein (AFP), (b) carcinoembryonic antigen (CEA), and (c) carbohydrate antigen 19.9 (CA19.9) in different treatment groups were measured. (d) Representative images of immunohistochemical staining with GST-p in different groups (scale bar = 100 μm). (e) The percentage of GST-p positive cells in different groups. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01](/cms/asset/43109671-4aea-4cac-a403-e153fb4b1490/kbie_a_1993716_f0003_oc.jpg)
Figure 4. Effect of MFP on the hepatic apoptosis markers in DEN/PB-induced HCC. (a) The levels of hepatic caspase-3 and (b) caspase-9 in different treatment groups were measured. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01
![Figure 4. Effect of MFP on the hepatic apoptosis markers in DEN/PB-induced HCC. (a) The levels of hepatic caspase-3 and (b) caspase-9 in different treatment groups were measured. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01](/cms/asset/cbe8caaa-adc7-446e-85c6-379139c28c4e/kbie_a_1993716_f0004_b.gif)
Figure 5. Effect of MFP on the hepatic inflammation markers in DEN/PB-induced HCC. (a) The levels of hepatic IL-1β, (b) TNF-α, and (c) NF-κB in different treatment groups were measured. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01
![Figure 5. Effect of MFP on the hepatic inflammation markers in DEN/PB-induced HCC. (a) The levels of hepatic IL-1β, (b) TNF-α, and (c) NF-κB in different treatment groups were measured. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01](/cms/asset/fbfb3d38-b8b8-4fc5-84ac-b72baf5c0ec7/kbie_a_1993716_f0005_b.gif)
Figure 6. mRNA expression in rat’s hepatic tissue with DEN/PB-induced HCC. The level of Bcl-2 (a), Bax (b), caspase-3 (c), and caspase-9 (d) in different treatment groups. (e) Representative images of immunohistochemical staining with Bcl-2 in different groups (scale bar = 100 μm). (f) The percentage of Bcl-2 positive cells in different groups. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01
![Figure 6. mRNA expression in rat’s hepatic tissue with DEN/PB-induced HCC. The level of Bcl-2 (a), Bax (b), caspase-3 (c), and caspase-9 (d) in different treatment groups. (e) Representative images of immunohistochemical staining with Bcl-2 in different groups (scale bar = 100 μm). (f) The percentage of Bcl-2 positive cells in different groups. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01](/cms/asset/eb6f758f-0fc9-42f8-a0ef-198a46e0ff35/kbie_a_1993716_f0006_oc.jpg)
Figure 7. mRNA expression in rat’s hepatic tissue with DEN/PB-induced HCC. The level of IL-1β (a), TNF-α (b), NF-κB (c), and MTH1 (d) in different treatment groups. (e) Representative images of immunohistochemical staining with NF-κB in different groups (scale bar = 100 μm). (f) The percentage of NF-κB positive cells in different groups. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01
![Figure 7. mRNA expression in rat’s hepatic tissue with DEN/PB-induced HCC. The level of IL-1β (a), TNF-α (b), NF-κB (c), and MTH1 (d) in different treatment groups. (e) Representative images of immunohistochemical staining with NF-κB in different groups (scale bar = 100 μm). (f) The percentage of NF-κB positive cells in different groups. ## Significant against Con group at P < 0.01. ** Significant against DEN/PB group at P < 0.01. * Significant against DEN/PB group at P < 0.05. & Significant against DEN/PB+HMFP group at P < 0.05. && Significant against DEN/PB+HMFP group at P < 0.01](/cms/asset/f94cf88b-3e13-4428-a426-e000cd60695d/kbie_a_1993716_f0007_oc.jpg)
Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.